Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals have signed a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of Metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes.
Subscribe to our email newsletter
Amylin said that the study will be conducted by researchers at The University of Texas (UT) Southwestern Medical Cente.
Prior studies at UT Southwestern conducted in animal models with type 1 diabetes showed an improvement in blood glucose, blood fats, and cholesterol following administration of the hormone.
Amylin stated that the clinical study will help to determine if similar improvements in glucose, and reduction of the amount of insulin required, can be achieved in people with type 1 diabetes.
JDRF Treatment Therapies assistant vice president Aaron Kowalski said that if effective in humans, Metreleptin, when used with insulin, could change the way people manage their disease.
Amylin R&D Strategic Relations vice president David Maggs said that they were pleased to partner on this important research program.
The research collaboration agreement between JDRF and Amylin is part of JDRF’s Industry Discovery and Development Partnership (IDDP) program through which JDRF partners with pharmaceutical, biotechnology and medical device companies focused on the discovery, development, and delivery of therapeutics and devices for type 1 diabetes and its complications.